Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 27;63(1):15.
doi: 10.1186/s42358-023-00295-2.

Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort

Francesco Molica Colella #  1   2 , Gaetano Zizzo #  3   4 , Vincenzo Parrino  5 , Maria Teresa Filosa  6 , Riccardo Cavaliere  7 , Francesco Fazio  8 , Aldo Biagio Molica Colella  6 , Antonino Mazzone  9
Affiliations

Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort

Francesco Molica Colella et al. Adv Rheumatol. .

Abstract

Background: Secukinumab has shown high efficacy in randomized controlled trials in both ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Here, we investigated its real-life effectiveness and tolerability in a cohort of AS and PsA patients.

Methods: We retrospectively analyzed medical records of outpatients with AS or PsA treated with secukinumab between December 2017 and December 2019. ASDAS-CRP and DAS28-CRP scores were used to measure axial and peripheral disease activity in AS and PsA, respectively. Data were collected at baseline and after 8, 24, and 52 weeks of treatment.

Results: Eighty-five adult patients with active disease (29 with AS and 56 with PsA; 23 males and 62 females) were treated. Overall, mean disease duration was 6.7 years and biologic-naïve patients were 85%. Significant reductions in ASDAS-CRP and DAS28-CRP were observed at all time-points. Body weight (in AS) and disease activity status at baseline (particularly in PsA) significantly affected disease activity changes. ASDAS-defined inactive disease and DAS28-defined remission were achieved in comparable proportions between AS and PsA patients, at both 24 weeks (45% and 46%) and 52 weeks (65.5% and 68%, respectively); male sex was found an independent predictor of positive response (OR 5.16, P = 0.027). After 52 weeks, achievement of at least low disease activity and drug retention were observed in 75% of patients. Secukinumab was well-tolerated and only mild injection-site reactions were recorded in 4 patients.

Conclusion: In a real-world setting, secukinumab confirmed great effectiveness and safety in both AS and PsA patients. The influence of gender on treatment response deserves further attention.

Keywords: ASDAS-CRP; Ankylosing Spondylitis (AS); Body weight; DAS28-CRP; Interleukin-17 (IL-17); Male sex; Psoriatic Arthritis (PsA); Secukinumab; Spondyloarthritis (SpA); Treatment..

PubMed Disclaimer

References

    1. Dougados M, Baeten D, Spondyloarthritis. Lancet. 2011 Jun 18;377(9783):2127-37. doi: https://doi.org/10.1016/S0140-6736(11)60071-8 . PMID: 21684383.
    1. Braun J, Sieper J, Ankylosing spondylitis. Lancet. 2007 Apr 21;369(9570):1379–1390. doi: https://doi.org/10.1016/S0140-6736(07)60635-7 . PMID: 17448825.
    1. Wallenius M, Skomsvoll JF, Koldingsnes W, Rødevand E, Mikkelsen K, Kaufmann C, Kvien TK. Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis. 2009 May;68(5):685–9. https://doi.org/10.1136/ard.2008.092049 . Epub 2008 May 29. PMID: 18511544.
    1. Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, Van den Bosch F, Olivieri I, Roussou E, Scarpato S, Sørensen IJ, Valle-Oñate R, Weber U, Wei J, Sieper J. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011 Jan;70(1):25–31. Epub 2010 Nov 24. PMID: 21109520.
    1. Feld J, Chandran V, Haroon N, Inman R, Gladman D. Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nat Rev Rheumatol. 2018 Jun;14(6):363–371. doi: https://doi.org/10.1038/s41584-018-0006-8 . PMID: 29752461.

Publication types